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Abstract
Pre-emptive culling is becoming increasingly questioned as ameans of controlling animal diseases, including classical swine fever
(CSF). This has prompted discussions on the use of emergency vaccination to control future CSF outbreaks in domestic pigs.
Despite a long history of safe use in endemic areas, there is a paucity of data on aspects important to emergency strategies, such
as how rapidly CSFV vaccines would protect against transmission, and if this protection is equivalent for all viral genotypes,
including highly divergent genotype 3 strains. To evaluate these questions, pigs were vaccinated with the RiemserH C-strain
vaccine at 1, 3 and 5 days prior to challenge with genotype 2.1 and 3.3 challenge strains. The vaccine provided equivalent
protection against clinical disease caused by for the two challenge strains and, as expected, protection was complete at 5 days
post-vaccination. Substantial protection was achieved after 3 days, which was sufficient to prevent transmission of the 3.3 strain
to animals in direct contact. Even by one day post-vaccination approximately half the animals were partially protected, and were
able to control the infection, indicating that a reduction of the infectious potential is achieved very rapidly after vaccination. There
was a close temporal correlation between T cell IFN-c responses and protection. Interestingly, compared to responses of animals
challenged 5 days after vaccination, challenge of animals 3 or 1 days post-vaccination resulted in impaired vaccine-induced T cell
responses. This, together with the failure to detect a T cell IFN-c response in unprotected and unvaccinated animals, indicates
that virulent CSFV can inhibit the potent antiviral host defences primed by C-strain in the early period post vaccination.
Citation: Graham SP, Everett HE, Haines FJ, Johns HL, Sosan OA, et al. (2012) Challenge of Pigs with Classical Swine Fever Viruses after C-Strain Vaccination
Reveals Remarkably Rapid Protection and Insights into Early Immunity. PLoS ONE 7(1): e29310. doi:10.1371/journal.pone.0029310
Editor: Ding Xiang Liu, Nanyang Technological University, Singapore
Received September 6, 2011; Accepted November 25, 2011; Published January 3, 2012
Copyright:  2012 Graham et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by project (SE0778) from the Department for Environment, Food and Rural Affairs of the United Kingdom. http://www.defra.
gov.uk/. Pathological investigations were supported by the European Commission’s Seventh Framework Programme (FP7/2007–2013) under grant agreement nu
228394 (NADIR) (http://cordis.europa.eu/fp7/home_en.html). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist. The AHVLA has no commercial connection with the manufacturer of the
vaccine used in this study, Riemser Arzneimittel AG, Germany.
* E-mail: Helen.crooke@ahvla.gsi.gov.uk
. These authors contributed equally to this work.
¤ Current address: Section of Virology, Imperial College London, London, United Kingdom
Introduction
A number of live attenuated classical swine fever (CSF) vaccines
have been developed by traditional methods such as passage in
tissue culture (e.g. Thiverval strain), or by serial passage in rabbits
(e.g. the Chinese or C-strain) [1]. These vaccines are remarkably
effective in abrogating the clinical signs of disease and are used to
control losses in areas where the disease is endemic [2]. Combined
with culling of infected animals, such vaccines have assisted in the
eradication of the disease from many areas of the world, and are
being applied to eliminate disease from wildlife reservoirs [3,4,5].
However, due to the inability to identify infected animals by
serology within a vaccinated population, the non-emergency use of
such live attenuated vaccines is banned in the EU [6] and current
strategies to control outbreaks are based on slaughter of all pigs on
infected holdings, establishment of protection and surveillance
zones, movement restrictions and, in some instances, pre-emptive
culling of neighbouring uninfected herds [3,6]. This policy can lead
to large scale economic and social consequences, which were most
strikingly demonstrated by the devastating outbreak that occurred
in the Netherlands, France, Belgium and Spain in 1997 [7,8]. A
much smaller outbreak in the UK in 2001 resulted in the
destruction of around 73,000 animals, 32,000 of which were in
herds pre-emptively slaughtered because they were considered as
dangerous contacts, although they were not subsequently identified
to be infected [9]. In the last decades the morality of culling healthy
animals for economic interests has been questioned, despite the fact
that food production animals are destined for slaughter anyway
[10]. This has led to a reconsideration of options for disease control,
including the use of emergency vaccination. Decisions on control
strategies are complex, will vary for different regions, and depend on
many factors, such as; herd density, production system(s), the
presence of susceptible wildlife, impact on export trade and current
opinions on economic versus ethical factors [11,12].
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Like pre-emptive culling, the aim of an emergency vaccination
strategy is to reduce virus spread from an infected herd. With
current legislation and available CSF vaccines, possible emergency
vaccination strategies include: 1) suppressive vaccination, where
animals in a zone around an identified premises are vaccinated
with live-attenuated vaccine and subsequently slaughtered (vacci-
nate-to-kill) or 2) protective vaccination, (vaccinate to live) where a
marker vaccine that allows identification of infection within a
vaccinated population is used. Unlike suppressive vaccination,
animals vaccinated under a protective strategy, and their products,
would be able to enter normal trade, [6,13,14]. The currently
licensed marker vaccine is not ideal in terms of efficacy, and the
accompanying differential test is not optimal for a rapid
emergency vaccination strategy [13,15,16,17] and many research
efforts are aimed at developing improved marker vaccines and
diagnostics [18,19]. To date, emergency vaccination strategies
have not been used in an outbreak, apart from transitionally in
Romania, and so conclusions about how well they may perform
are largely reliant on simulations [12,20].
Although live attenuated vaccines have been used prophylati-
cally for many years, some questions remain about how effective
they would be at controlling CSF in a suppressive emergency
vaccination campaign. To prevent infection of neighbouring
herds, suppressive vaccination should induce a rapid protection
that prevents dissemination of virus. The C-strain vaccine provides
solid protection against challenge by 7 days post-vaccination (dpv)
[1] and there are indications that protection occurs even earlier
[21,22,23]. Dewulf and colleagues [24] demonstrated that
vaccination with C-strain on the same day as challenge prevented
transmission to vaccinated pen mates. However, fewer data are
available on how rapidly vaccination prevents transmission of virus
to susceptible animals in these very short intervals.
For CSF-free areas, introductions of CSFV could originate from
any region of the world and so an emergency vaccine should
provide protection against all CSFV strains. C-strain, and the
majority of live attenuated CSF vaccines, belong to genotype 1.1
and are considered to be effective against all genotypes.
Experimental studies have demonstrated vaccine efficacy against
for genotype 1 [25,26] and genotype 2 strains [24,27]. However,
there is evidence that genotype 2 strains have replaced genotype 1
viruses as the dominant genotype in China, an area where
vaccination is mandatory, implying that antigenic differences
between genotypes may impact to some extent on vaccine efficacy
[28,29]. In addition, very little information is available on vaccine
efficacy against viruses of the genotype 3 subgroups. Parchar-
iyanon and co-workers [30] described 18 genetically diverse
genotype 3.3 isolates, two of which, CBR/94/2 and CBR/93,
have a distinct antigenic profile and which, notably, only react
poorly with Mab WH303 which targets a principal neutralising
epitope TAVSPTTLRP of the viral E2 envelope protein [31]. The
ability of C-strain to protect against clinical signs upon challenge
with CBR/94/2 two weeks after vaccination has been demon-
strated [32]. However, the mechanism of protection has not been
elucidated and it is unclear if C-strain vaccine protects efficiently
against transmission of genetically and antigenically diverse strains
at very short periods post-vaccination.
It is generally accepted that neutralising antibody induced by
vaccination with C-strain, which is detected from 2–3 weeks post-
vaccination [33], is a major protective mechanism. However, for a
rapid emergency vaccine, the mechanism of protection induced
prior to this time is of greater importance. Since virus-specific T
cell IFN-c responses can be detected 7 days post-vaccination it has
been suggested that they may mediate protection in the absence of
antibody [27,34]. C-strain-induced T cell responses have been
reported in a limited number of studies. Virus-specific CD4+ and
CD8+ T cell IFN-c responses, targeting the major viral envelope
glycoprotein E2 and the non-structural viral protein NS3, have
been observed following vaccination [35,36,37]. MHC class I
restricted cytotoxic T lymphocyte responses, directed against
epitopes on both E2 and NS3 have also been described,
[35,36,38]. We have recently shown that immunisation of pigs
with C-strain vaccine induced a robust, virus-specific, IFN-c
response detectable from at least 9 days post-vaccination but these
responses could not be detected in pigs experimentally infected
with a recent, moderately virulent, field isolate [39]. While IFN-c
appears to serve as a marker for anti-CSFV cell-mediated
responses, the data underlying a correlation with protection are
limited.
With a view to providing additional information for those
formulating emergency vaccination policies and to understand the
role that T cell responses may have in vaccine-induced, rapid
immunity we have investigated the speed with which the C-strain
vaccine affords protection of susceptible in-contact animals, after
challenge with two diverse CSFV strains, as well as the kinetics
and magnitude of T cell responses.
Materials and Methods
Ethics statement
The project was approved by the Animal Health and Veterinary
Laboratories Agency ethics committee and all procedures were
conducted in accordance with the UK Animals (Scientific
Procedures) Act 1986 under project licence permit number PPL
70_6559).
Animals and Viruses
Large White/Landrace cross male pigs, 9 weeks of age were
purchased from a local commercial source. During the acclima-
tisation period, biothermal microchips (Destron Technologies Inc.)
were implanted subcutaneously behind the left ear for temperature
monitoring. CSFV strain UK2000/7.1 [40] is a genotype 2.1 virus
isolated from a domestic pig during an outbreak in the UK in
2000. CBR/93 was kindly provided by S. Parchariyanon [30].
Viruses were propagated in the PK-15 swine kidney cell line [41].
Lyophilized live attenuated RiemserH C-strain CSFV vaccine (AC
Riemser Schweinepestvakzine, Riemser Arzneimittel AG, Ger-
many) was reconstituted with the supplied buffer as directed,
immediately prior to vaccination.
Challenge experiments
The protection afforded by vaccination against challenge with
the UK2000/7.1 and CBR/93 strains was assessed in two
independent challenge experiments. In both experiments three
groups of 6 pigs were vaccinated intramuscularly with 2 ml of
reconstituted vaccine, either 5, 3 or 1 day prior to challenge.
Three additional unvaccinated pigs were housed with each group
of vaccinated animals in order to monitor prevention of infection
of in-contact animals. A fourth group, consisting of 6 animals,
remained unvaccinated. Four of these animals were challenged
whilst the remaining two were not and served to monitor the
extent of in-contact infection. On day 0 animals to be challenged
were moved to other rooms and challenged with an intranasal
aerosol using a MAD 300 device (Wolfe Tory Medical, USA).
Titration of the inoculae indicated challenge doses were 104.6
TCID50 for UK2000/7.1 and 10
5.1 TCID50 for CBR/93. After
24 hours, the challenged animals were re-introduced to the in-
contact animals in the original rooms.
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Throughout the duration of the study, temperatures and clinical
signs were recorded twice daily, using a slightly modified scoring
scheme as described previously [42,43]. EDTA blood and serum
samples were obtained prior to vaccination and then at 2 to 3 day
intervals. Nasal swabs were collected at 1–3 day intervals. Animals
were euthanized by IM administration of Ketamine/Rompun
sedative followed by IV administration of 20% sodium pentobar-
bitone solution.
Virus quantification in blood and nasal swabs,
haematology and pathology
Nasal swabs were soaked in 1 ml PBS, agitated and then
centrifuged at 524 g for 7 min. Blood samples were collected in
EDTA vacutainers (BD Biosciences). Viral RNA was extracted
from 140 ml nasal swab suspension or 50 ml EDTA blood using a
Qiagen BioRobot Universal instrument. For swabs, a QIAamp 96
DNA Swab BioRobot kit (Qiagen) was used. For blood, the All-
for-One Nucleic acid kit (Qiagen) was used with a QIAamp One
For All UNIV rcV72 programme, which includes a proteinase K
digestion step. Viral RNA was quantified using a qRT-PCR one-
step Superscript III Platinum kit (Invitrogen) as described
previously [43]. Platelets and CD 45+ white blood cells present
in EDTA blood were quantified by flow cytometry [43]. Post
mortem examinations followed standard operational procedures,
and any observed lesions were recorded. Tissue samples were fixed
in buffered formalin and routinely processed into paraffin wax.
Tissue sections were stained with haematoxylin and eosin for
histopathological analysis. Macropathology and histopathological
scoring systems were used as previously described [43].
Quantification of neutralising antibodies
Blood was collected in serum separation vacutainers (BD
Biosciences) and serum was obtained by centrifugation at 524 g
for 10 min. The measurement of CSFV neutralising antibody
titres in sera was determined using a standard virus neutralisation
peroxidise-linked assay using Alfort 187 CSFV and PK-15 cells
[41].
Analysis of IFN-c production from in vitro stimulated
peripheral blood cells
Heparinised blood was collected in heparin vacutainers (BD
Biosciences) from pigs every 3 days post-vaccination/challenge.
Leukocytes were prepared using a standard protocol. In brief,
blood was centrifuged at 800 g for 10 min and visible ‘buffy coat’
material aspirated. Contaminating erythrocytes were lysed by
addition of Pharmlyse Buffer (BD Biosciences) and leukocytes
incubated for 10 min at RT before being washed three times in
Hank’s buffered salt solution (HBSS) (Invitrogen). Cells were
finally resuspended in RPMI-1640 medium supplemented with
10% foetal calf serum (FCS) and antibiotics (all from Invitrogen).
Cell densities were determined by flow cytometry, adjusted to
56106 cells/ml and 100 ml transferred to wells of a 96 well round-
bottom plate. Cells were stimulated by the addition of an equal
volume of medium containing C-strain CSFV at a multiplicity of
infection (MOI) of 1. For negative control samples, a mock
inoculum, prepared from an uninfected PK-15 cell lysate, was
added in an equivalent volume. Cells were incubated for 72 hours
at 37uC in a humidified 5% CO2 atmosphere, then resuspended
by repeated pipetting and centrifuged at 4006 g for 5 min. Cell
free supernatants were removed and immediately stored at 280uC
until analysis. IFN-c was measured in the culture supernatants,
diluted 1:2 in standard diluent buffer using a swine IFN-c ELISA
according to the manufacturer’s instructions (Biosource, Invitro-
gen) and absorbance at 440 nm read using a FLUOstar OPTIMA
microplate reader (BMG Labtech, UK).
Statistical analysis
ANOVA was used for the analysis of fixed effects on different
traits using GraphPad Prism 5 (Prism 5 for Windows, Version
5.01, GraphPad Software, Inc. La Jolla, USA). A plot of the total
[log10] viraemia versus virus-specific IFN-c or neutralising
antibody responses suggested negative exponential relationships
between them, and thus a linear regression was carried out with
log total viraemia as the dependent variable and the total virus-
specific IFN-c or neutralising antibody responses as the indepen-
dent variables. Significant differences in pathological parameters
between the vaccinated and unvaccinated animals were analysed
with Mann-Whitney-U test.
Results
Vaccination five days prior to challenge protected
animals against clinical disease and prevented infection
of in-contact animals, for both challenge strains
Unvaccinated animals inoculated with either the genotype 2.1
(UK2000/7.1) or genotype 3 (CBR/93) challenge viruses had
similar parameters of infection. Initial clinical signs were observed
between 6 to 9 days post challenge (dpc) (Table 1), which
coincided with the onset of leukopenia (Fig. 1), thrombocytopenia
(data not shown) and detection of high levels of RNA in the blood
(Fig. 2A). Clinical signs then increased and animals were
euthanized between 14 and 19 dpc for welfare reasons. Post
mortem examination confirmed pathological changes consistent
with CSF (Table 2). In both experiments, animals placed in-
contact with the unvaccinated animals became infected, with
clinical signs initially being observed at 15 dpc, 7 days after viral
RNA was detected in nasal swab samples from the inoculated
animals (Fig. 2A). In-contact animals had haematology and
pathology parameters (Table 2) consistent with CSF and infection
was confirmed by detection of CSFV RNA in blood. Vaccination
of animals five days prior to challenge with either virus prevented
all clinical signs of disease. Leukocyte and platelet numbers
remained normal, viral RNA was not detected above the
inconclusive range of the assay in blood or nasal secretions
(Fig. 2B), minimal pathological lesions were observed and the in-
contact animals did not develop any trace of infection, indicating
that vaccination provided solid protection against clinical disease
and prevented subsequent dissemination of these heterogeneous
challenge strains.
Vaccination at very short time points prior to challenge
confers some, but not complete, protection against
clinical disease and virus dissemination
In the UK2000/7.I challenge experiment one of the animals
vaccinated 3 days prior to challenge developed clinical signs soon
after challenge which were not considered to be directly due to
CSFV. This animal, which was treated with and responded to
antibiotics, had high levels of CSFV RNA in both blood and nasal
swabs (Fig. 2C) and post mortem examination revealed multifocal
bronchopneumonia. The other vaccinated and challenged animals
in this group did not manifest any overt clinical signs, although a
slight decrease in leukocyte counts was noted in the first week post
challenge (Fig. 1), which coincided with a low, transient level of
viral RNA in the blood. Low levels of viral RNA were detected in
nasal swab samples of these five animals, however this was only
subsequent to high levels of virus were being secreted by the
CSFV Vaccine Rapid Protection and Immune Insights
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Table 1. Clinical parameters.
Challenge Experimental Mean clinical score(a) at days post challenge Requiring Infection
virus group Euthanasia(b) of in-contacts(c)
26 to 24 23 to 21 0 to 2 3 to 5 6 to 8 9 to 11 12 to 14 15 to 17 18 to 20
UK2000 unvaccinated 0 (1) 0 (0) 0 (1) 1 (1) 3 (2) 4 (2) 5 (2) 5 (1) 4/4 Yes
7.1 Day -5 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (1) 0/6 No
Day -3 0 (0) 0 (0) 0 (0) 2 (5) 1 (3) 2 (2) 1 (2) 1 (2) 0 (1) 1/6 Yes
Day -1 0 (0) 0 (0) 0 (1) 0 (0) 1 (1) 2 (2) 3 (2) 2 (1) 1 (2) 3/6 Yes
CBR/93 unvaccinated 0 (0) 0 (0) 0 (1) 0 (1) 1 (2) 3 (2) 3 (2) 4 (2) 4 (2) 4/4 Yes
Day -5 0 (0) 0 (0) 0 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0/6 No
Day -3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0/6 No
Day -1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 2 (2) 2 (1) 2 (2) 2/6 Yes
a)Mean clinical scores over 3 day period. Bracketed numbers indicate the standard deviation.
b)Number animals that developed clinical signs and were euthanized before the end of the experiment.
c)In contact animals were identified as infected by detection of CSFV RNA in blood.
doi:10.1371/journal.pone.0029310.t001
Figure 1. Vaccine induced protection against leukopenia. Leucokyte numbers remained at pre-vaccination levels throughout the experiment
in animals vaccinated five days prior to challenge with A) UK2000/7.1 or B) CBR/93 (filled circles), whereas a significant (P,0.05) decrease occurred
rapidly after challenge in unvaccinated animals (open circles) and animals vaccinated one day before challenge that developed clinical signs and
were euthanized prior to the end of the experiment (open triangles). A smaller, non significant, decrease in leukocyte numbers was observed in
animals vaccinated one day prior to challenge that did not develop clinical signs (filled triangles) and those vaccinated three days prior to challenge
(filled squares). n = number of animals in groups vaccinated on day prior to challenge that either developed signs and were euthanized or remained
clinically healthy. Data are mean leukocyte counts for each group of pigs. Error bars represent SEM.
doi:10.1371/journal.pone.0029310.g001
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antibiotic-treated animal (Fig. 2C). Viral RNA was detected in the
blood of the three in-contact animals in this group from dpc 12,
they began to develop obvious signs at dpc19 and were euthanized
between dpc 19 and 22. In contrast, for the genotype 3.3 (CBR/
93) strain none of the animals vaccinated 3 days prior to challenge
had any notable clinical changes or decrease in leukocytes
numbers (Fig. 1). One of the vaccinated animals in this group
had intermediate levels of viral RNA in the blood from 6 dpc
which then decreased (Fig. 2C). However, no viral RNA was
detected in nasal swab samples from any animals in this group and
the in-contact animals in this group did not become infected.
In the groups vaccinated 1 day before challenge, with either of the
challenge strains, some of the vaccinated animals had clinical signs
from 7–10 dpc and were euthanized for welfare reasons, whereas
the other vaccinated animals remained apparently healthy for the
duration of the experiment (Table 1). The haematological,
pathological and virological data clearly delineated two different
outcomes of challenge at this short period post-vaccination (Figure 1,
2D, Table 2). The animals that developed clinical signs and were
euthanized early were not protected by the vaccine, with all
parameters indicating a disease resembling the unvaccinated control
group. The remaining animals were infected by the challenge virus
but were able to control the infection; haematology returned to
normal, viral RNA concentrations in the blood decreased and only
low levels of viral RNA were detected in nasal secretions. Despite
this evidence of a degree of clinical protection among the vaccinates,
all in-contact animals in both day21 vaccination groups developed
CSF, indicating that transmission was not prevented when animals
were challenged 24 hours after vaccination.
Virus-specific T cell IFN-c responses correlate with
complete protection induced by vaccination 5 days
before challenge whereas both neutralising antibody
and T cell IFN-c responses contribute to protection at
later time points
Since both neutralising antibody and virus-specific T cell
responses may exert inhibitory effects on CSFV, we investigated
the kinetics of these responses and compared this to the course of
viraemia observed following vaccination and challenge (Fig. 3).
Virus-specific T cell IFN-c responses for both challenge strains
were measured longitudinally following in vitro stimulation of
peripheral blood leukocytes with C-strain CSFV (Fig. 3A). Of the
challenge time-points studied CSFV specific IFN-c T cell
responses were strongest in the animals vaccinated 5 days before
challenge, which peaked at 6 dpc (11 days post-vaccination) and
remained elevated (p,0.05). For all the day -3 vaccinates, and the
day -1 vaccinates that controlled the infection, virus specific IFN-c
responses were detected from day 9 and 12 post-challenge,
respectively, and were significantly reduced compared to the day -
5 vaccinates (p,0.05). No virus specific IFN-c responses were
detected from any of the day-1 vaccinated animals that succumbed
to the challenge infection or from the unvaccinated challenge
control pigs. In contrast, virus neutralising antibody titres were
detected from day 12 post-challenge in the groups vaccinated on
day -5, -3 and the day -1 vaccinates that recovered from the
challenge infection (Fig. 3B). Neutralising antibody was only
detected from day 15 post-challenge in the day -1 vaccinates that
succumbed to infection and the challenge controls. The signifi-
Table 2. Pathological parameters.
Challenge Experimental Euthanized Pathological score
virus group early(a)
Vaccinated+Challenged In-contact
Macro- Histo- Macro- Histo-
Unvaccinated 29 (4.1) 64 (7.6) 21 (4.2) 51 (0.7)
UK2000/ Day -5 11 (2.2)* 11 (2.3)* 8 (2.1) 14 (2.1)
7.1 Day -3 16 (3.5)* 32 (8.2)* 26 (2.0) 43 (7.6)
Day -1 No n= 3 14 (4.5) 29 (7.2) 25 (1.5) 51 (12.9)
Yes n = 3 31 (8.5) 59 (13.9)
CBR/93 Unvaccinated 31 (5.1) 59 (8.6) 29 (7.1) 55 (11.3)
Day -5 8 (3.7)* 9 (3.9)* 7 (0.0) 11 (6.9)
Day -3 8 (1.8)* 15 (4.2)* 5 (1.2) 14 (4.6)
Day -1 No n= 4 16 (6.4)* 32(13)* 18 (2.0) 34 (5.3)
Yes n = 2 40 (11) 73 (11)
a)Number of animals that developed clinical signs and were euthanized early or had no or few signs and survived until the end of the experiment.
*Significant difference to unvaccinated control group (P,0.05).
doi:10.1371/journal.pone.0029310.t002
Figure 2. Kinetics of vaccine induced prevention or reduction of viral RNA in blood and nasal secretions. Viral RNA concentrations,
determined by real time RT-PCR, in blood (solid lines) and nasal swab samples (dashed lines). A) High levels of viral RNA were detected in blood soon
after challenge in unvaccinated animals (open circles), with nasal secretions becoming RNA positive 5–6 days later. B) No viral RNA, or very low levels
in the inconclusive range of the assay, was detected in blood or nasal secretion of animals vaccinated 5 days prior to challenge (filled circles). C) High
levels of viral RNA was detected in blood and nasal swab samples of one of the animals vaccinated 3 days prior to challenge with UK2000/7.1. An
intermediate level of viral RNA was present in blood of one animal vaccinated 3 days prior to challenge with CBR/93 (open squares), whereas the
remaining animals in these groups in both experiments (filled squares) had either a transient low level, or no, viral RNA in blood, and either no or
intermediate levels of RNA in nasal secretions. D) Animals vaccinated one day prior to challenge either developed clinical disease and were
euthanized by 18 dpc (open triangles) or remained healthy for the duration of the experiment (filled triangles).
doi:10.1371/journal.pone.0029310.g002
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cance of the responses became further apparent when they were
correlated with the viraemia detected in these animals (Fig. 3C). A
log-linear regression analysis showed a negative exponential
relationship between the total [log10] viraemia and both the
virus-specific IFN-c and neutralising antibody responses (p,0.05).
The day -5 vaccinates had robust IFN-c responses, and antibody
appeared later in the absence of a detectable viraemia, whereas the
day -1 and unvaccinated animals that succumbed to challenge had
undetectable IFN-c responses, delayed antibody responses and
uncontrolled viraemia. Interestingly, the decline and disappear-
ance of viraemia in the day -3 vaccinates and the day -1 vaccinates
that controlled the challenge infection, occurred coincidently with
the appearance of virus-specific IFN-c responses and neutralising
antibody.
Discussion
C-strain vaccines, such as the RiemserH vaccine, are known to
be highly efficacious at preventing clinical disease. However,
despite their use in the field for many years, few standard
vaccination experiments have investigated the protection afforded
against diverse genotype 3 viruses, and the ability of vaccination to
prevent infection of naive in-contact animals is often not
considered. Genotype 3 viruses are less common than the other
CSFV genotypes and have, thus far, largely been restricted to Asia:
A distinct clade of genotype 3.2 viruses were isolated in Korea
between 1988 and 1999 [44], 18 genotype 3.3 viruses were
isolated in Thailand between 1988 and 1996 [30] and genotype
3.4 viruses have been found in Japan [45] and were endemic in
Taiwan until 1996 [46,47]. Prophylactic vaccination, for example
with LPC and GPE2 vaccines [45,46], has reduced the incidence
of CSF in these regions and group 3 viruses have not been
reported recently. However, the diversity of the viruses within this
group implies that they have been circulating for some time and
the possibility of these viruses re-emerging, for example from wild
suidae, remains. This study provides conclusive evidence that the
RiemserH vaccine, which is a tissue-culture adapted version of C-
strain, provides an equivalent and complete protection by 5 days
post-vaccination against disease and spread of genotype 3 and
genotype 2 viruses.
As well as being a representative of genotype 3, the CBR/93
strain is of additional interest as it is one of only two known isolates
that do not bind to monoclonal antibodies against the highly
conserved, immunodominant TAVSPTLLR epitope [32]. Al-
though we observed no difference in the rapid vaccine protection
afforded against this strain and the genotype 2.1 isolate, the
efficacy of long term protection, when the role of neutralising
antibodies is likely to be of greater importance, still needs to be
assessed.
The extent of protection, particularly against virus transmission,
induced by C-strain vaccination at times earlier than 5 days post-
vaccination has not been described in detail. For an emergency
vaccination, the rapidity with which an intervention will prevent
spread of virus is of utmost importance. This knowledge is crucial
for making decisions on use of emergency vaccination strategies
compared to a pre-emptive slaughter policy. These investigations
indicate that by 3 days post-vaccination, the majority of animals
were substantially protected from clinical disease and viraemia and
the amount of virus present in nasal secretions was markedly
reduced. The difference between the fates of the in contact animals
in the groups vaccinated 3 days prior to challenge in the two
experiments was, almost certainly, due to the presence of one
animal with underlying health issues in the UK2000/7.1 challenge
experiment that was unable to control the disease. This animal
Figure 3. Association of virus-specific IFN-c and serum
neutralising antibody responses with viraemia. Pigs were
vaccinated with C-strain CSFV on days -5, -3 or -1 and were then
challenged, together with groups of unvaccinated pigs, with UK2000/
7.1 or CBR93 CSFV isolates. According to clinical outcome following
challenge, the day -1 vaccinated pigs were separated into two groups;
(recov) animals that experienced mild signs followed by recovery and
(euth) animals that developed severe signs necessitating euthanasia. (A)
Peripheral blood leukocyte (PBL) IFN-c responses were measured by
ELISA following in vitro stimulation with C-strain CSFV or an uninfected
cell preparation (Mock) and data presented as the mock corrected
values. (B) Serum neutralisation titres (SNT) against the CSFV reference
strain Alfort 187 were assessed in vitro. (C) Viraemia in was measured by
qRT-PCR and expressed as log10 viral RNA copies/ml blood. Data from
the UK2000/7.1 and CBR/93 experiments were combined and results
expressed as the mean data for each group of pigs and error bars
represent SEM.
doi:10.1371/journal.pone.0029310.g003
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had a high level of virus in nasal secretions that was sufficient to
result in infection of the in-contact animals. The lower level of
virus present in nasal swabs of other animals in this pen, at a time
when they were no longer viraemic, is likely to originate from
environmental contamination derived from this one animal rather
than secretion from the other animals themselves. Interestingly,
although one animal vaccinated 3 days prior to challenge with
CBR/93 had an intermediate level of virus in the blood,
vaccination provided sufficient protection to prevent nasal
secretion and infection of the in-contact animals. Even as early
as one day post-vaccination a proportion of the animals were
protected to some degree. Although, this was insufficient to
prevent infection of animals in direct contact, there was a
reduction in the overall level of virus excreted into the
environment. As virus transmission is affected by the amount of
virus excreted [48], these results indicate that vaccination would
reduce the potential for virus to spread between farms from as
early as one day post-vaccination.
The disadvantage of current live attenuated vaccines for CSF is
the inability to distinguish vaccinated and infected animals by
serology, leading to the potential for field virus to hide within a
vaccinated population. The vaccinated animals in this study that
became infected were either not protected, with viral and
immunological parameters identical to unvaccinated animals, or
were protected to a certain extent. The majority of infected
animals with no protection would likely be clinically apparent and,
as only very low levels of vaccine virus are found in blood after
intramuscular vaccination [49], a high level of virus in blood
would be indicative of field infection. Such infections could
subsequently be easily distinguished by genetic-based differential
tests, such as sequencing or discriminatory PCRs, which have been
applied successfully during oral vaccination campaigns in wild
boar [50]. Those animals that are partially protected and harbour
lower levels of virus would be more difficult to identify, but
strategies such as inclusion of unvaccinated sentinel animals within
a vaccinated herd, in combination with discriminatory PCR
assays, could be applied as part of an emergency vaccination and
testing regime, so as to substantially reduce the risk that the field
virus would remain undetected. As highlighted by the animal with
a low level viraemia, which did not transmit virus to animals in
direct contact, these partially protected animals would be of
minimal risk of further disease transmission [14]. However, the
risk posed by the level of virus present in meat and products from
such vaccinated and infected animals, if it were allowed to be
traded, remains a question that deserves further research.
It has previously been reported that CSFV C-strain can protect
pigs 7 days post vaccination, which precedes the appearance of
virus-neutralising serum antibodies, but not T cell responses
[1,34], and animals protected from challenge by vaccination with
an E2 based DNA vaccine have increased levels of CSFV specific
IFN-c producing cells compared to unvaccinated controls [51].
However, the temporally associated stratification of protection in
the vaccination study we present here has, for the first time,
convincingly shown a correlation between the induction of T cell
responses and the protection afforded. Whilst it remains to be
determined if this correlation represents a direct causal interaction
of IFN-c response with CSFV, it highlights that efforts toward
future generation CSFV vaccines, particularly those that would be
used for emergency strategies, should consider this a critical
correlate of protection.
In conclusion these data have addressed important questions
about how this vaccine might perform if applied in an emergency
vaccination strategy. As well as demonstrating broad protection
against diverse genotypes these studies demonstrate how rapidly a
reduction in between-herd transmission could be achieved.
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